You are here

Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE)

In this pragmatic, patient-centered clinical trial, we will compare the effectiveness of two doses of aspirin (81 mg and 325 mg) currently in widespread use in the United States in the secondary-prevention population of patients with established atherosclerotic cardiovascular disease (ASCVD). The trial will use a novel format that uses existing electronic health records (EHRs), as well as a web-based patient portal to collect patient-reported outcomes (PROs), and available patient encounter data to supplement/support the EHR. A total of 20,000 high-risk patients with ASCVD will be randomly assigned (in an open-label fashion) in a 1:1 ratio to instructions to use a daily aspirin dose of either 81 mg or 325 mg daily. We expect the entire sample of patients will be enrolled over 24 months, with a maximum follow-up of 30 months.


Other Information:



Back to list of Initiatives